September 27, 2016
SymBio Pharmaceuticals Limited
Fuminori Yoshida
Representative Director
President and Chief Executive Officer
(Securities Code: 4582)

Onconova Announces Results of End-of-Phase 2 Meeting with FDA regarding Plans for Pivotal Phase 3 Oral Rigosertib/Azacitidine Combination Trial for Higher-risk Myelodysplastic Syndromes

TOKYO, Japan, September 27, 2016 -- SymBio Pharmaceuticals Limited (Headquarters: Tokyo, "SymBio,") announced today that its U.S. partner, Onconova Therapeutics, Inc. (Headquarters: Newtown, PA, "Onconova") announced on September 26, 2016 (EST) its receipt of the End-of-Phase 2 meeting minutes from the U.S. Food and Drug Administration (FDA) regarding the plans for a pivotal Phase 3 oral rigosertib/azacitidine combination trial for higher-risk myelodysplastic syndromes (MDS).

In its news release, Onconova stated that the interactions with the FDA resulted in agreement on the choice of overall response rate as the primary endpoint, and that based on the discussions, the company will design a pivotal Phase 3 trial for higher-risk MDS. For more details in this press release, please visit Onconova's homepage at
http://investor.onconova.com/releases.cfm

As Onconova will likely continue regulatory discussions with the FDA in order to finalize the Phase 3 trial plans, SymBio will make announcements when Onconova posts press releases regarding the progress of such discussions.

SymBio obtained the licensing rights for rigosertib from Onconova in July, 2011 and retains the development rights for Japan and Korea.

[Contact]

Investor Relations
Tel: +81 (0)3 5472 1125

About Myelodysplastic Syndromes (MDS)

MDS patients often require frequent blood transfusions due to the development of severe anemia (decrease in the number of red blood cells), with a high rate of progression to acute myelogenous leukemia (AML). There are an estimated 11,000 MDS patients in Japan alone, with the number of cases expected to increase as the population ages. MDS and AML are widely recognized as two blood disorders that are difficult to manage given the limited therapeutic options available for patients, particularly for patients who have a drug-resistant form of the disease. A high unmet medical need clearly exists for the establishment of new effective therapies to treat both lower-risk MDS and higher-risk MDS.

About Onconova Therapeutics, Inc.

Onconova Therapeutics, Inc. is a clinical-stage biopharmaceutical company focused on discovering and developing novel products to treat cancer. Onconova's clinical and pre-clinical stage drug development candidates are derived from its extensive chemical library and are designed to work against specific cellular pathways that are important in cancer cells, while causing minimal damage to normal cells. In addition to rigosertib, Onconova's most advanced drug candidate under development, two other drug candidates are in clinical trials and several other compounds in the pre-clinical stage of development. For more information, please visit http://www.onconova.com.

About SymBio Pharmaceuticals Limited

SymBio Pharmaceuticals Limited was established in March, 2005 by Fuminori Yoshida who previously served concurrently as Corporate VP of Amgen Inc. and founding President of Amgen Japan. In May, 2016 the Company incorporated its wholly-owned subsidiary in the U.S., called SymBio Pharma USA, Inc. (Headquarters: Menlo Park, California, President: Mr. Fuminori Yoshida). The Company's underlying corporate mission is to "deliver hope to patients in need" as it aspires to be a leading global specialty biopharmaceutical company dedicated to addressing underserved medical needs with main therapeutic focus in oncology, hematology and pain management.